Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer. Dr. Shah will lead the Company's global clinical development and medical affairs at an inflection point as Nuevocor prepares to initiate a first-in-human clinical study of NVC-001 in patients with LMNA-associated dilated cardiomyopathy (DCM), one of the most aggressive forms of genetic heart disease. logo (PRNewsfoto/Nuevocor) A board-certified heart failure and transplant cardiologist, Dr. Shah brings more than two decades of experience in cardiovascular medicine and drug development across academia, NIH, and industry, including leadership roles in both biotech and CRO organizations. Most recently, she served as Chief Medical Officer of CTI Clinical Trial & Consulting, a specialty CRO, where she oversaw medical strategy across a broad portfolio of complex clinical programs spanning rare disease, gene therapy, and cardiovascular indications
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket to sell PRV for $180m to advance gene therapy pipeline [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherBusiness Wire
- Rocket Pharmaceuticals (RCKT) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (e+)" to "sell (d-)".MarketBeat
- Chronic Granulomatous Disease (CGD) Market Analysis and Outlook Report 2026-2036 - Emerging Gene Therapies, Lentiviral Vector-based Therapies and CRISPR-Cas9 Gene Editing, Ignite Hope [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) had its price target raised by Bank of America Corporation from $8.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
RCKT
Earnings
- 2/26/26 - Beat
RCKT
Sec Filings
- 4/28/26 - Form 8-K
- 4/27/26 - Form SC
- 4/6/26 - Form ARS
- RCKT's page on the SEC website